Abstract 1704P
Background
Value frameworks such as American Society of Clinical Oncology Value Framework (ASCO-VF) and European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) can be sensitive to control arms of randomized trials (RCTs). Standard of care changes over time. We explored clinical value based on appropriateness of control arm and its change over time.
Methods
We searched Drugs@FDA to identify new cancer drugs approved based on RCTs between January 2012 and December 2021, excluding trials with overlap between experimental and control arm. Appropriateness of control arm was based on published ESMO and NCCN guidelines both 1 year prior to start of accrual (as defined by ClinicalTrials.gov) and at time of drug approval. Control arm was defined as suboptimal if the strength of recommendation was 2B-3 for NCCN, III-V / C-E for ESMO guidelines and/or if prior RCT data showed that the control arm was inferior to an available alternative. Substantial clinical benefit was defined as ASCO-VF threshold score ≥45 and ESMO-MCBS grade A or B (curative intent) and 4 or 5 (palliative intent).
Results
We identified 55 RCTs supporting the approval of 32 drugs. Substantial benefit was observed in 65% and 55%, using ESMO-MCBS and ASCO-VF. Prior to accrual, appropriate control arm therapy was associated with non-significantly higher odds of clinical benefit using ESMO-MCBS with NCCN (OR 3.19, P=.23), but not ESMO guidelines (OR 1.29, P=.79). At the time of drug approvals associations were similar (OR 3.03, P=.06 and 1.17, P=.80). For ASCO-VF, appropriate control arm therapy was associated with non-significantly increased odds of clinical benefit (OR 5.52, P=.14) for both guidelines. These associations were not observed at the time of drug approval (OR 0.81, P=.69 for NCCN and 0.81, P=.72 for ESMO). Results were similar for RCTs performed exclusively in palliative intent.
Conclusions
ASCO-VF appears sensitive to change in appropriateness of control group therapy over time. ESMO-MCBS appears more consistent. Heterogeneity was observed based on scale, guideline and timepoint. Further exploration of impact of control group therapy on value frameworks is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22